MARC details
| 000 -LEADER |
|---|
| fixed length control field |
05630cam a2200505 i 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20250919005553.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
151007s2014 flua b 001 0 eng |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781466593862 |
| Qualifying information |
(hardback : acid-free paper) |
| Terms of availability |
RM352.58 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
1466593865 |
| Qualifying information |
(hardback : acid-free paper) |
| 039 #9 - LEVEL OF BIBLIOGRAPHIC CONTROL AND CODING DETAIL [OBSOLETE] |
|---|
| Level of rules in bibliographic description |
201510201216 |
| Level of effort used to assign nonsubject heading access points |
zainol |
| y |
10-07-2015 |
| z |
fida |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
DLC |
| Language of cataloging |
eng |
| Description conventions |
rda |
| Transcribing agency |
DLC |
| Modifying agency |
YDX |
| -- |
YDXCP |
| -- |
NLM |
| -- |
VET |
| -- |
CRCPR |
| -- |
OCLCQ |
| -- |
BTCTA |
| -- |
UKMGB |
| -- |
BDX |
| -- |
CDX |
| 040 ## - CATALOGING SOURCE |
|---|
| Modifying agency |
UKM |
| Description conventions |
rda |
| 090 ## - LOCALLY ASSIGNED LC-TYPE CALL NUMBER (OCLC); LOCAL CALL NUMBER (RLIN) |
|---|
| Classification number (OCLC) (R) ; Classification number, CALL (RLIN) (NR) |
QV38.5.C641 2014 9 |
| 090 ## - LOCALLY ASSIGNED LC-TYPE CALL NUMBER (OCLC); LOCAL CALL NUMBER (RLIN) |
|---|
| Classification number (OCLC) (R) ; Classification number, CALL (RLIN) (NR) |
QV 38.5 |
| Local cutter number (OCLC) ; Book number/undivided call number, CALL (RLIN) |
. C641 2014 9 |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Clinical and statistical considerations in personalized medicine / |
| Statement of responsibility, etc. |
edited by Claudio Carini, Pfizer, Cambridge, Massachusetts, USA, Sandeep Menon, Pfizer, Cambridge, Massachusetts, USA, Mark Chang, AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, USA. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Boca Raton : |
| Name of producer, publisher, distributor, manufacturer |
CRC Press/Taylor & Francis Group, |
| Date of production, publication, distribution, manufacture, or copyright notice |
[2014] |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
@2014 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xvi, 344 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
24 cm. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
unmediated |
| Media type code |
n |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Carrier type code |
nc |
| Source |
rdacarrier |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
Chapman & Hall/CRC biostatistics series |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Includes bibliographical references and index. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
1. Biomarkers for drug development : the time is now! / Claudio Carini and Attila Seyhan -- 2. RNAi screens : triumphs and tribulations / Attila Seyhan and Claudio Carini -- 3. Current advances in epigenetics / Ewan Hunter and Alexandre Akoulitchev -- 4. Biomarkers and precision medicine : the case of rare diseases / Candida Fratazzi and Claudio Carini -- 5. Biomarker-informed adaptive design / Jing Wang, Mark Chang, and Sandeep Menon -- 6. Fitting the dose : adaptive staggered dose design / Joseph Wu, Sandeep Menon, and Mark Chang -- 7. Evidence-based adaptive statistical decision and design strategies for maximizing the efficiency of clinical oncology development programs with predictive biomarkers / Cong Chen and Robert A. Beckman -- 8. Biomarker identification in clinical trials / Ilya Lipkovich and Alex Dmitrienko -- 9. Multiplicity in pharmacogenomics / Lingyun Liu, Fredrick Immermann, and Sandeep Menon -- 10. Patient-reported outcomes in personalized medicine / Demissie Alemayehu and Joseph C. Cappelleri -- 11. Regulatory issues in use of biomarkers in drug development / Aloka G. Chakravarty. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
'Personalized medicine has the potential to change the way we think about, identify, and manage health problems. In the pharmaceutical industry, it is already having an exciting impact on both clinical research and patient care. This impact will continue to grow as our understanding and technologies improve. With contributions from well-known industry leaders in clinical development, this book covers the practical aspects of personalized medicine, focusing on issues that have direct application in the industry. Topics include designs for targeted therapy, adaptive designs, evidence-based adaptive statistical decisions, and design strategies for maximizing the efficiency of clinical oncology'-- |
| Assigning source |
Provided by publisher. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
'Preface The successful utilization of biomarkers in clinical development and, indeed, realization of personalized medicine require a close collaboration among different stakeholders: clinicians, biostatisticians, regulators, commercial colleagues, and so on. For this reason, we invited experts from different fields of expertise to address the opportunities and challenges, and discuss recent advancements related to biomarkers and their translation into clinical development. The first four chapters discuss biomarker development from a clinical perspective ranging from introduction to biomarkers to recent advances in RNAi screens, epigenetics, and rare disease as targets for personalized medicine approaches. Chapters 5 through 10 are devoted to considerations from a statistical perspective, and the last chapter addresses the regulatory issues in biomarker utilization. A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as pathological process or response to a therapeutic intervention. Although there is nothing new about biomarkers such as glucose for diabetes and blood pressure for hypertension, the current focus on molecular biomarkers has taken the center stage in the development of molecular medicine. Molecular diagnostic technologies have enabled the discovery of molecular biomarkers and are assisting in the definition of the pathogenic mechanism of diseases. Biomarkers represent the basis of the development of diagnostic assays as well as the target for drug discovery. Biomarkers can help monitoring drugs effect in clinical trials as well as in clinical practice'-- |
| Assigning source |
Provided by publisher. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacogenetics |
| General subdivision |
statistics & numerical data. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Biological Markers. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Drug Discovery |
| General subdivision |
statistics & numerical data. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
MATHEMATICS |
| General subdivision |
Probability & Statistics |
| -- |
General. |
| Source of heading or term |
bisacsh |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
MEDICAL |
| General subdivision |
Internal Medicine. |
| Source of heading or term |
bisacsh |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
MEDICAL |
| General subdivision |
Pharmacology. |
| Source of heading or term |
bisacsh |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Carini, Claudio |
| Relator term |
editor |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Menon, Sandeep M., |
| Relator term |
editor |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Chang, Mark, |
| Relator term |
editor |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Chapman & Hall/CRC biostatistics series (Unnumbered) |
| 907 ## - LOCAL DATA ELEMENT G, LDG (RLIN) |
|---|
| a |
.b16214997 |
| b |
2019-11-12 |
| c |
2019-11-12 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
AM |
| Suppress in OPAC |
No |
| Call number prefix |
QV38.5.C641 2014 9 |
| 914 ## - VTLS Number |
|---|
| VTLS Number |
vtls003594120 |
| 990 ## - EQUIVALENCES OR CROSS-REFERENCES [LOCAL, CANADA] |
|---|
| Link information for 9XX fields |
zr |
| 991 ## - LOCAL NOTE (NAMA FAKULTI/INSTITUT/PUSAT) |
|---|
| a |
Fakulti Farmasi, KKL |
| 998 ## - LOCAL CONTROL INFORMATION (RLIN) |
|---|
| Library |
PERPUSTAKAAN DR ABDUL LATIFF |
| Operator's initials, OID (RLIN) |
2015-07-10 |
| Cataloger's initials, CIN (RLIN) |
m |
| Material Type (Sierra) |
Printed Books |
| Language |
English |
| Country |
|
| -- |
0 |
| -- |
.b16214997 |
